IN2014DN10889A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10889A
IN2014DN10889A IN10889DEN2014A IN2014DN10889A IN 2014DN10889 A IN2014DN10889 A IN 2014DN10889A IN 10889DEN2014 A IN10889DEN2014 A IN 10889DEN2014A IN 2014DN10889 A IN2014DN10889 A IN 2014DN10889A
Authority
IN
India
Prior art keywords
cell
car
conjugate
drug
molecule
Prior art date
Application number
Other languages
English (en)
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IN2014DN10889A publication Critical patent/IN2014DN10889A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IN10889DEN2014 2012-07-13 2013-07-12 IN2014DN10889A (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671518P 2012-07-13 2012-07-13
PCT/US2013/050272 WO2014011987A1 (en) 2012-07-13 2013-07-12 Compositions and methods for regulating car t cells

Publications (1)

Publication Number Publication Date
IN2014DN10889A true IN2014DN10889A (cg-RX-API-DMAC10.html) 2015-09-11

Family

ID=49916567

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10889DEN2014 IN2014DN10889A (cg-RX-API-DMAC10.html) 2012-07-13 2013-07-12

Country Status (14)

Country Link
US (3) US20150140019A1 (cg-RX-API-DMAC10.html)
EP (1) EP2872218A4 (cg-RX-API-DMAC10.html)
JP (1) JP2015525765A (cg-RX-API-DMAC10.html)
KR (1) KR20150030724A (cg-RX-API-DMAC10.html)
CN (1) CN104507537A (cg-RX-API-DMAC10.html)
AU (1) AU2013289970A1 (cg-RX-API-DMAC10.html)
BR (1) BR112015000310A2 (cg-RX-API-DMAC10.html)
CA (1) CA2878856A1 (cg-RX-API-DMAC10.html)
EA (1) EA201590207A1 (cg-RX-API-DMAC10.html)
IL (1) IL236679A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN10889A (cg-RX-API-DMAC10.html)
MX (1) MX2015000428A (cg-RX-API-DMAC10.html)
SG (1) SG11201408398UA (cg-RX-API-DMAC10.html)
WO (1) WO2014011987A1 (cg-RX-API-DMAC10.html)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
MX374929B (es) 2013-02-20 2025-03-06 Novartis Ag RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
RU2741120C2 (ru) 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
WO2016073875A1 (en) * 2014-11-06 2016-05-12 University Of Maryland, Baltimore CD8α AND T CELL RECEPTOR VARIANTS AND METHODS OF USING SAME IN MODULATING IMMUNE CELL RESPONSES
AU2015367317A1 (en) * 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
US10273300B2 (en) 2014-12-29 2019-04-30 The Trustees Of The University Of Pennsylvania Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
JP6779909B2 (ja) 2015-01-26 2020-11-04 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ）
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
DK3280729T3 (da) 2015-04-08 2022-07-25 Novartis Ag Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
EP3313872A4 (en) * 2015-06-25 2019-03-20 iCell Gene Therapeutics LLC CHIMERIC ANTIGEN RECEPTORS (CARS) COMPOSITIONS AND METHOD FOR USE THEREOF
CN109476722A (zh) * 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
EP3339320A4 (en) * 2015-08-17 2019-01-23 Seoul National University R&DB Foundation CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF
CN108135932A (zh) * 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
EP4218777A3 (en) 2015-08-28 2023-08-23 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
MX2019003886A (es) 2016-10-07 2019-08-05 Novartis Ag Receptores de antigenos quimericos para el tratamiento del cancer.
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018073394A1 (en) * 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018187356A2 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
EP3645036A1 (en) 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CN111629749A (zh) 2017-10-18 2020-09-04 诺华股份有限公司 用于选择性蛋白质降解的组合物和方法
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CA3124457A1 (en) 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
JP2022525781A (ja) 2019-03-20 2022-05-19 マサチューセッツ インスティテュート オブ テクノロジー 免疫細胞療法における両親媒性物質の使用およびそのための組成物
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
JP2022547570A (ja) 2019-09-12 2022-11-14 ザ・ブロード・インスティテュート・インコーポレイテッド 操作済みのアデノ随伴ウイルスキャプシド
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
PH12022551290A1 (en) 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
MX2022006391A (es) 2019-11-26 2022-06-24 Novartis Ag Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
US20240108653A1 (en) * 2021-02-05 2024-04-04 University Of Utah Research Foundation Compositions and methods for treating with car cells
EP4375292A4 (en) * 2021-07-21 2025-01-08 Korea Research Institute of Bioscience and Biotechnology NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS FOR EXPRESSION THEREOF
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
CA2404340C (en) * 2000-03-29 2012-10-16 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
SG10201900535UA (en) * 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
CA2621502A1 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
DE102010039018B4 (de) * 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
US9701758B2 (en) * 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide

Also Published As

Publication number Publication date
EA201590207A1 (ru) 2015-05-29
CA2878856A1 (en) 2014-01-16
CN104507537A (zh) 2015-04-08
AU2013289970A1 (en) 2015-01-22
JP2015525765A (ja) 2015-09-07
WO2014011987A1 (en) 2014-01-16
US20190367610A1 (en) 2019-12-05
EP2872218A4 (en) 2016-07-06
IL236679A0 (en) 2015-02-26
BR112015000310A2 (pt) 2017-06-27
US20150140019A1 (en) 2015-05-21
MX2015000428A (es) 2015-03-12
SG11201408398UA (en) 2015-02-27
KR20150030724A (ko) 2015-03-20
US20230034117A1 (en) 2023-02-02
EP2872218A1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
IN2014DN10889A (cg-RX-API-DMAC10.html)
NZ705910A (en) Pyrrolobenzodiazepines and conjugates thereof
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
IN2014DN09098A (cg-RX-API-DMAC10.html)
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
NZ701573A (en) Carriers for improved drug delivery
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
NZ631144A (en) Compositions and methods for transmucosal absorption
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12015500664A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
PH12013502441B1 (en) Therapeutic nuclease compositions and methods
IN2014DN11099A (cg-RX-API-DMAC10.html)
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
WO2012038504A3 (en) Breast cancer therapeutics
WO2013163303A3 (en) Transferrin receptor aptamers and aptamer-targeted delivery
IN2015MN00001A (cg-RX-API-DMAC10.html)
IN2014MN01945A (cg-RX-API-DMAC10.html)
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
IN2014MN01944A (cg-RX-API-DMAC10.html)
PH12015500663A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use
IN2014DN09437A (cg-RX-API-DMAC10.html)
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor